Sorrento Therapeutics Inc., of San Diego, received a Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases in support of its antibody therapeutics and vaccines for Staphylococcus aureus, including methicillin-resistant strains. The Phase I grant is worth $600,000 over two years, with possible Phase II funding of $1 million per year for three years.